Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Oct;34(10):908-917.
doi: 10.1002/da.22673. Epub 2017 Jul 17.

Treatment of Premenstrual Dysphoria With Continuous Versus Intermittent Dosing of Oral Contraceptives: Results of a Three-Arm Randomized Controlled Trial

Affiliations
Free PMC article
Randomized Controlled Trial

Treatment of Premenstrual Dysphoria With Continuous Versus Intermittent Dosing of Oral Contraceptives: Results of a Three-Arm Randomized Controlled Trial

Tory A Eisenlohr-Moul et al. Depress Anxiety. .
Free PMC article

Abstract

Background: Although traditionally dosed combined oral contraceptives (COCs) (21 days of active pills, 7 days of inactive pills) have not been demonstrated as superior to placebo for the treatment of premenstrual dysphoria (PMD), some randomized controlled trials (RCTs) indicate that oral contraceptives administered with a shortened or eliminated hormone-free interval are superior to placebo. However, results of such trials are mixed, and no existing studies have directly compared continuous and intermittent dosing schedules of the same oral contraceptive. The present study compared placebo, intermittent dosing of oral contraceptives, and continuous dosing of contraceptives for the treatment of PMD.

Methods: Fifty-five women with prospectively confirmed PMD completed a three-arm, RCT in which they were randomized to 3 months of placebo (n = 22), intermittent drospirenone/ethinyl estradiol dosed on a 21-7 schedule (n = 17), or continuous drospirenone/estradiol (n = 16) following a baseline assessment month.

Results: All three groups demonstrated similar, robust reductions in premenstrual symptoms over time. A marked placebo response was observed.

Conclusions: The study fails to replicate a uniquely beneficial effect of continuous COC on PMD. Additional work is needed to understand the psychosocial context bolstering the placebo response in women with PMD.

Trial registration: ClinicalTrials.gov NCT00927095.

Keywords: oral contraceptives; premenstrual syndrome; randomized controlled trial.

Conflict of interest statement

The authors have no conflicts of interest to report.

Figures

Figure 1
Figure 1
CONSORT Diagram.
Figure 2
Figure 2
Daily total symptoms (Mean DRSP summed score) across the menstrual cycle by treatment group and study month.

Similar articles

See all similar articles

Cited by 2 articles

Publication types

MeSH terms

Substances

Associated data

Feedback